Retrovirus are a group of virus that belong to the family Retroviridae and they characteristically carry their genetic blueprint in the form of ribonucleic acid (RNA). The anti-retroviral drugs hinder the multiplication of these viruses rather than killing them. Anti-retroviral drugs are medications for the treatment of infection by retroviruses, primarily HIV. The global anti-retroviral drugs market is expected to register a CAGR of 4.0% during the forecast period (2018 - 2023).
Increasing Prevalence of HIV
According to the U.S. Department of Health & Human Services, there were approximately 36.7 million people worldwide that were living with HIV/AIDS, out of which 2.1 million were children. An estimated 1.8 million individuals worldwide became newly infected with HIV in 2016. Anti-retrovirals (ARVs) are the foundation of HIV/AIDS management, as currently there is no cure or vaccine available for HIV. In individuals with a non-resistant strain of HIV, the antiretroviral treatment can suppress the replication of HIV in about 80% of cases. This huge patient pool shows that the market for anti-retroviral drugs will grow at rapid CAGR in the forecast period.
Increasing investment in R&D of antivirals, rising prevalence rate of retroviral infections, and high unmet needs of people are some of the other factors contributing to the growth of the market.
Side Effects of the Drugs
There have been noted side effects of antiretroviral drugs in some patients, like appetite loss, lipodystrophy, diarrhea, fatigue, and high triglyceride & cholesterol levels, and it has been a pressing concern that needs to be addressed.
Additionally, lack of effective drugs and increasing failure rate of drug candidates are also restraining the anti-retroviral drugs market growth.
North America to Dominate the Market
The global anti-retroviral drugs market report is segmented by drug type and geography. Based on geography, it is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and South America.
North America dominates the market due to better healthcare infrastructure and R&D capabilities.
Major Players: Roche, Gilead, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott, AstraZeneca, Merck, Johnson and Johnson, Boehringer Ingelheim, and Novartis AG, among others.
Reasons to Purchase This Report
- Market analysis for the global anti-retroviral drugs market, with region-specific assessments and competition analysis on a global and regional scale
- Analyzing various perspectives of the industry with the help of Porter’s five forces analysis
- Identifying the treatment type that is expected to dominate the market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players
- 3-month analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
- This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power Of Suppliers
5.2.2 Bargaining Power Of Consumers
5.2.3 Threats Of New Entrants
5.2.4 Threat Of Substitute Product And Services
5.2.5 Competitive Rivalry Within The Industry
6. Drivers, Restraints, Opportunities, And Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Investment in R&D of Antivirals
6.1.2 Increasing Prevalence of HIV and other retroviral infections
6.1.3 High Unmet Needs
6.2 Market Restraints
6.2.1 Lack Of Effective Drugs
6.2.2 Increasing Faliure Rate Of Drug Candidates
6.2.3 Side Effects Of Drugs
6.4 Key Challenges
7. Market Segmentation
7.1 By Drug Type
7.1.1 Protease Inhibitors
7.1.2 Non-Nucleoside Reverse Transcriptase Inhibitors
7.1.3 Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors
7.1.4 Integrase Inhibitors
7.2 By Geography
7.2.1 North America
188.8.131.52 Rest Of Europe
184.108.40.206 South Korea
220.127.116.11 Rest Of APAC
7.2.4 Middle East & Africa
18.104.22.168 South Africa
22.214.171.124 Rest Of Middle East & Africa
7.2.5 South America
126.96.36.199 Rest Of South America
8. Competitive Landscape
8.1 Mergers And Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.8 Johnson and Johnson
9.9 Boehringer Ingelheim
9.10 Novartis AG
*List not Exhaustive
10. Future Outlook Of The Market